Christophe Cisarovsky, Sofiya Latifyan, Claire Perrinjaquet, Dominik Berthold, Angela Orcurto
Revue medicale suisse 2021 May 19Intravesical immunotherapy with Calmette-Guerin bacillus (BCG) have been used since decades for the treatment of non-muscle invasive bladder cancer and is a proof of principle that immunotherapy works for this malignancy. Since 2016, immune checkpoint inhibitors (ICI) demonstrated clinical benefits in locally advanced or metastatic bladder cancer, providing potentially durable tumor control in first line therapy or upon relapse after standard treatments. Ongoing clinical trials aim to demonstrate the efficiency of ICI for the treatment of localized disease.
Christophe Cisarovsky, Sofiya Latifyan, Claire Perrinjaquet, Dominik Berthold, Angela Orcurto. Immunotherapy for bladder cancer in 2021]. Revue medicale suisse. 2021 May 19;17(739):974-977
PMID: 34009756
View Full Text